Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Dow
Moodys
Johnson and Johnson
Baxter
Colorcon
Fish and Richardson
US Department of Justice
AstraZeneca

Generated: February 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ULIPRISTAL ACETATE

« Back to Dashboard

Clinical Trials for Ulipristal Acetate

Trial ID Title Status Sponsor Phase Summary
NCT00290251 Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 Completed HRA Pharma Phase 2 This study will evaluate whether the experimental drug ulipristal acetate can shrink uterine fibroids in pre-menopausal women.
NCT00290251 Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2 This study will evaluate whether the experimental drug ulipristal acetate can shrink uterine fibroids in pre-menopausal women.
NCT00740831 PGL4001 Versus GnRH-agonist in Uterine Myomas Completed PregLem SA Phase 3 This trial will assess the efficacy and safety of PGL4001 versus GnRH agonist, over a 3-month period for the pre-operative treatment of pre-menopausal women suffering from excessive uterine bleeding due to uterine myoma.
NCT00755755 PGL4001 Versus Placebo in Uterine Myomas Completed PregLem SA Phase 3 This trial will assess the efficacy and safety of PGL4001 with concomitant iron administration versus placebo with concomitant iron administration, over a 3-month period for the pre-operative treatment of pre-menopausal women suffering from excessive uterine bleeding due to uterine myoma.
NCT01107106 Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women Completed HRA Pharma N/A The purpose of this observational study is to assess the safety and tolerability of ellaOne® in routine conditions of use for emergency contraception in postmenarcheal adolescents and adult women who want to prevent pregnancy up to 5 days after unprotected sexual intercourse.
NCT01156857 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata Completed PregLem SA Phase 3 This is a multicentre, Phase III, efficacy and safety open-label study with PGL4001 10mg once daily for 3 months, blinded towards the administration of progestin or placebo after end of PGL4001 treatment.
NCT01252069 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study) Completed PregLem SA Phase 3 This is the long-term extension of a phase III, efficacy and safety open-label (protocol PGL09-026) with PGL4001 10mg tablets once daily for three months, blinded towards the administration of progestin or placebo tablets after end of PGL4001 treatment. This extension study consists of three periods of 3 months open-label PGL4001 treatment, each followed by ten days of double-blind treatment with progestin or placebo and then a period without treatment.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ulipristal Acetate

Condition Name

Condition Name for Ulipristal Acetate
Intervention Trials
Contraception 11
Uterine Fibroids 5
Fibroid 4
Adenomyosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ulipristal Acetate
Intervention Trials
Leiomyoma 19
Myofibroma 18
Hemorrhage 8
Emergencies 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ulipristal Acetate

Trials by Country

Trials by Country for Ulipristal Acetate
Location Trials
United States 116
Italy 6
Spain 5
Belgium 4
Poland 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ulipristal Acetate
Location Trials
Colorado 8
Oregon 7
New York 7
Illinois 7
Pennsylvania 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ulipristal Acetate

Clinical Trial Phase

Clinical Trial Phase for Ulipristal Acetate
Clinical Trial Phase Trials
Phase 4 17
Phase 3 11
Phase 2 6
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ulipristal Acetate
Clinical Trial Phase Trials
Not yet recruiting 15
Recruiting 14
Completed 12
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ulipristal Acetate

Sponsor Name

Sponsor Name for Ulipristal Acetate
Sponsor Trials
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 5
PregLem SA 5
HRA Pharma 4
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ulipristal Acetate
Sponsor Trials
Other 40
Industry 16
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
QuintilesIMS
Daiichi Sankyo
Harvard Business School
Queensland Health
US Department of Justice
Dow
Deloitte
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.